Literature DB >> 21222371

Natriuretic peptides and atrial fibrillation.

D Marsiliani1, F Buccelletti, A Carroccia, E Gilardi, N Gentiloni Silveri, F Franceschi.   

Abstract

BACKGROUND AND
OBJECTIVE: Atrial fibrillation (AF) is the most common arrhythmia in the medical practice, it is associated with an increased total and cardiovascular mortality, as well as cardiovascular morbidity, including stroke and heart failure. AF is encountered in different medical specialties including cardiology, family medicine and emergency medicine as well. Treatment goal is to minimize stroke risk but also taking into account the quality of life. Therefore rate or a rhythm control strategies must be carefully selected. This review focuses on natriuretic polypeptides (NPs) as potential useful markers in AF patients management. EVIDENCE AND INFORMATION SOURCES: Pubmed was searched for natriuretic peptides and atrial fibrillation. Pertinent abstracts were reviewed by the Authors and the articles fully evaluated when considered pertinent. STATE OF THE ART: NP biology and physiology is described and general application in heart failure outlined. With regard to AF, the role of NP as predictor of cardioversion is reviewed and discussed. Patients eligible for rhythm control not always respond to treatment. Classic markers for a suitable cardioversion, such an echocardiography, are not immediately available in most settings. NP might be a resource predicting cardioversion (or not) upon patient's presentation. PROSPECTIVES: Biomarkers, such NPs, might be used to predict treatment response other than in heart failure.
CONCLUSIONS: In AF management, NT-ProBNP is a promising tool helping physicians to choose rhythm or rate control strategy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21222371

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  5 in total

1.  Natriuretic peptides in heart failure: where we are, where we are going.

Authors:  Michele Correale; Antonio Totaro; Carmen Greco; Natale Daniele Brunetti; Matteo Di Biase
Journal:  Intern Emerg Med       Date:  2011-05-01       Impact factor: 3.397

2.  A brain natriuretic peptide-based prediction model for atrial fibrillation after thoracic surgery: Development and internal validation.

Authors:  David Amar; Hao Zhang; Kay See Tan; Daniel Piening; Valerie W Rusch; David R Jones
Journal:  J Thorac Cardiovasc Surg       Date:  2019-01-31       Impact factor: 5.209

3.  N-terminal pro brain natriuretic peptide eliminates the prognostic effect of atrial fibrillation in patients with chronic heart failure.

Authors:  Johannes Schnorbach; Hanna Fröhlich; Tobias Täger; Anna Corletto; Hugo A Katus; Lutz Frankenstein
Journal:  ESC Heart Fail       Date:  2019-07-01

Review 4.  Atrial and Brain Natriuretic Peptides- Benefits and Limits of their use in Cardiovascular Diseases.

Authors:  Mustafa Edme Roxana; TÃrtea Georgică; Donoiu Ionuț; Moise Gianina; Florescu Cristina
Journal:  Curr Cardiol Rev       Date:  2019

5.  Intravenous Magnesium Sulfate Reduces the Need for Antiarrhythmics during Acute-Onset Atrial Fibrillation in Emergency and Critical Care.

Authors:  Emanuele Gilardi; Fulvio Pomero; Enrico Ravera; Andrea Piccioni; Michele Cosimo Santoro; Nicola Bonadia; Annamaria Carnicelli; Luca Di Maurizio; Luca Sabia; Yaroslava Longhitano; Angela Saviano; Veronica Ojetti; Gabriele Savioli; Christian Zanza; Francesco Franceschi
Journal:  J Clin Med       Date:  2022-09-21       Impact factor: 4.964

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.